Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.30 |
| ▸ | PKM | P14618 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2278363 | 0.98 | TSHR (0.42) | TSHRNFKB1CYP2C19ALDH1A1SMN1; SMN2 | |
| Lithium SCHEMBL29816832 | 0.95 | TSHR (0.41) | TSHRNFKB1CYP2C19ALDH1A1SMN1; SMN2 | |
| SCHEMBL28088669 | 0.77 | TSHR (0.45) | TSHRNFKB1CYP2C19ALDH1A1 | |
| SCHEMBL10574423 | 0.75 | TSHR (0.43) | TSHRNFKB1CYP2C19SMN1; SMN2 | |
| SCHEMBL28448964 | 0.75 | TSHR (0.43) | TSHRNFKB1CYP2C19 | |
| SCHEMBL9067554 | 0.75 | TSHR (0.48) | TSHRNFKB1CYP2C19 | |
| SCHEMBL8613670 | 0.75 | TSHR (0.43) | TSHRNFKB1CYP2C19SMN1; SMN2 | |
| SCHEMBL771854 | 0.73 | TSHR (0.42) | TSHRNFKB1CYP2C19 | |
| SCHEMBL8527302 | 0.73 | TSHR (0.42) | TSHRNFKB1CYP2C19 | |
| Hydrochloric Acid SCHEMBL11196712 | 0.73 | TSHR (0.47) | TSHRNFKB1CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 55 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114945627-A | Cation-exchange and anion-exchange polymers and (blended) membranes prepared from polymers containing highly fluorinated aromatic groups by nucleophilic substitution | 斯图加特大学 | 2022-08-26 | — | — | CN | disclosed |
| EP-1434763-B1 | BETA-LACTAMYL VASOPRESSIN V1A ANTAGONISTS | AZEVAN PHARMACEUTICALS INC (US) | 2018-01-17 | — | — | EP | disclosed |
| US-9422225-B2 | Substituted phenethylamines with serotoninergic and/or norepinephrinergic activity | AUSPEX PHARMACEUTICALS, INC. (US) | 2016-08-23 | — | — | US | disclosed |
| US-8426400-B2 | β-lactamyl phenylalanine, cysteine, and serine vasopressin antagonists | AZEVAN PHARMACEUTICALS, INC. (US) | 2013-04-23 | — | — | US | disclosed |
| US-20120220765-A1 | BETA-LACTAMYL PHENYLALANINE, CYSTEINE, AND SERINE VASOPRESSIN ANTAGONISTS | KOPPEL GARY A (US) | 2012-08-30 | — | — | US | disclosed |
| US-8138226-B2 | Substituted phenethylamines with serotoninergic and/or norepinephrinergic activity | AUSPEX PHARMACEUTICALS (US) | 2012-03-20 | — | — | US | disclosed |
| US-8048874-B2 | Beta-lactamyl phenylalanine, cysteine, and serine vasopressin antagonists | AZEVAN PHARMACEUTICALS, INC. (US) | 2011-11-01 | — | — | US | disclosed |
| US-20110070192-A1 | Method of preparation of novel nucleoside analogs and uses | AUSPEX PHARMACEUTICALS, INC. | 2011-03-24 | — | — | US | disclosed |
| US-20100137244-A1 | PREPARATION AND UTILITY OF HMG-COA REDUCTASE INHIBITORS | AUSPEX PHARMACEUTICALS, INC. (US) | 2010-06-03 | — | — | US | disclosed |
| US-7691904-B2 | pH sensitive prodrugs of 2,6-diisopropylphenol | AUSPEX PHARMACEUTICALS, INC (US) | 2010-04-06 | — | — | US | disclosed |
| US-20030162962-A1 | Streptogramin derivatives, their preparation and compositions containing them | AVENTIS PHARMA S.A. (FR) | 2003-08-28 | — | — | US | disclosed |
| US-6610680-B1 | Administering as adjuncts in heart failure or as antithrombotic agents, treatment of obsessive-compulsive disorder, aggressive disorders, depression and anxiety | ELI LILLY AND COMPANY | 2003-08-26 | — | — | US | disclosed |
| WO-2003031407-A2 | β-LACTAMYL VASOPRESSIN VlaANTAGONISTS | SERENIX PHARMACEUTICALS, LLC (US) | 2003-04-17 | — | — | WO | disclosed |
| US-6521611-B2 | 2-(azetidin-2-on-1-yl) acetic acid derivatives; treatment of obsessive-compulsive disorder | ELI LILLY AND COMPANY | 2003-02-18 | — | — | US | disclosed |
| EP-0939632-A4 | NON-PEPTIDYL VASOPRESSIN V1a ANTAGONISTS | LILLY CO ELI (US) | 2002-09-25 | — | — | EP | disclosed |
| US-20020049187-A1 | Non-peptidyl vasopressin V1a antagonists | BRUNS ROBERT F (US) | 2002-04-25 | — | — | US | disclosed |
| US-6204260-B1 | 2-(AZETIDIN-2-ON-1-YL)ACETIC ACID DERIVATIVES | ELI LILLY AND COMPANY | 2001-03-20 | — | — | US | disclosed |
| EP-0939632-A1 | NON-PEPTIDYL VASOPRESSIN V1a ANTAGONISTS | ELI LILLY AND COMPANY (US) | 1999-09-08 | — | — | EP | disclosed |
| WO-1997030707-A1 | NON-PEPTIDYL VASOPRESSIN V1a ANTAGONISTS | ELI LILLY AND COMPANY (US) | 1997-08-28 | — | — | WO | disclosed |
| US-3988325-A | 7-Carboxy or 2,2,2-trichloroethoxy carbonyl- cephalosporins | ELI LILLY AND COMPANY (US) | 1976-10-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110070192-A1 | Method of preparation of novel nucleoside analogs and uses | RNGTT, TYMP, SLC29A1 | TSHR 2840/4885NFKB1 1945/4885CYP2C19 1515/4885 |
| US-20100137244-A1 | PREPARATION AND UTILITY OF HMG-COA REDUCTASE INHIBITORS | HMGCR, COASY, ECHS1 | TSHR 4130/4885NFKB1 3564/4885CYP2C19 361/4885 |
| US-20120220765-A1 | BETA-LACTAMYL PHENYLALANINE, CYSTEINE, AND SERINE VASOPRESSIN ANTAGONISTS | AVPR2, AVPR1A, AVPR1B | TSHR 406/4885NFKB1 2572/4885CYP2C19 2400/4885 |
| US-20020049187-A1 | Non-peptidyl vasopressin V1a antagonists | AVPR1A, AVPR2, AVPR1B | TSHR 153/4885NFKB1 2284/4885CYP2C19 2260/4885 |
| US-20030162962-A1 | Streptogramin derivatives, their preparation and compositions containing them | MRPL21, SPG11, NGLY1 | TSHR 3687/4885NFKB1 656/4885CYP2C19 399/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.